Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts
Crinetics Pharmaceuticals (NASDAQ:CRNX) has garnered an average "Moderate Buy" rating from ten brokerages, with an average 12-month price target of $76.13. The company recently reported a quarterly loss slightly wider than expected but exceeded revenue estimates with significant year-over-year growth. Despite institutional ownership of 98.51%, notable insider selling has occurred, while stock performance shows the company trading below its fifty and two-hundred day moving averages.
Precision Trading with Crinetics Pharmaceuticals Inc. (CRNX) Risk Zones
This article provides a precision trading analysis for Crinetics Pharmaceuticals Inc. (CRNX), highlighting weak near-term sentiment but strong long-term support. It outlines three AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss zones. The analysis emphasizes risk management and multi-timeframe signal assessment for different investment horizons.
CRNX Maintained by Evercore ISI Group -- Price Target Lowered to $88
Evercore ISI Group has reiterated an "Outperform" rating for Crinetics Pharmaceuticals (CRNX) but has lowered its price target from $89.00 to $88.00. Despite a GF Value™ indicating the stock is significantly undervalued, the company faces challenges with a low GF Score™ and notable insider selling. Investors are advised to proceed with caution due to mixed signals and the "Possible Value Trap" classification.
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Q1 2026 Revenue Growth And Wider Net Loss
Crinetics Pharmaceuticals (CRNX) reported Q1 2026 revenues of US$10.73 million, a significant increase from the previous year, but also a wider net loss of US$127.85 million. Despite short-term share price declines, longer-term returns are strong, and analysts suggest the stock is significantly undervalued, with a fair value of $82.43 per share according to Simply Wall St's narrative or US$432.31 per share based on their DCF model. This valuation gap is attributed to the potential of PALSONIFY in acromegaly care, though launch uncertainties and cash burn remain risks.
T. Rowe Price (NASDAQ: CRNX) reports 5.1% holding in Crinetics
T. Rowe Price Associates, Inc. has filed an amendment (Schedule 13G/A) reporting a beneficial ownership of 5,355,011 shares of Crinetics Pharmaceuticals (CRNX) common stock, which represents 5.1% of the class. The filing indicates sole voting power over 5,352,428 shares and sole dispositive power over all 5,355,011 shares. Notably, the filing includes a declarative statement from T. Rowe Price Associates, Inc. expressly denying beneficial ownership, despite reporting the substantial holding.
Driehaus reduces holding in Crinetics Pharmaceuticals (NASDAQ: CRNX) to 6.11%
Driehaus Capital Management LLC has amended its Schedule 13G/A, reporting a reduced beneficial ownership in Crinetics Pharmaceuticals (CRNX) to 6.11% as of March 31, 2026. This marks a decrease from their prior stake of 7.54% reported on December 31, 2023. The shares, totaling 6,395,922, are held on a fully discretionary basis for multiple clients, with Driehaus sharing both voting and dispositive power.
Wellington Management Group (CRNX) reports 7.79% beneficial stake in Crinetics
Wellington Management Group LLP has filed an amended Schedule 13G/A, disclosing a 7.79% beneficial ownership of Crinetics Pharmaceuticals, Inc. common stock, held across various affiliated entities. The filing indicates shared voting and dispositive power, consistent with a passive investment approach rather than an active attempt to control the company. This ownership represents 8,157,204 shares with shared dispositive power and 7,143,677 shares with shared voting power.
Industry Analysts Just Upgraded Their Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Revenue Forecasts By 11%
Industry analysts have significantly upgraded Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) revenue forecasts for 2026 by 11%, now expecting US$69 million, representing a 279% improvement over the last 12 months. Despite this optimistic revenue outlook, loss per share estimates remain steady at US$4.79, and the consensus price target of US$83.21 has not changed, suggesting ongoing losses are a larger valuation factor than increasing sales. The company is predicted to achieve an accelerated annual growth of 5x by the end of 2026, significantly outpacing its historical 29% per annum growth and the broader industry's 8.7% annual growth forecast.
Industry Analysts Just Upgraded Their Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Revenue Forecasts By 11%
Industry analysts have significantly upgraded their revenue forecasts for Crinetics Pharmaceuticals, Inc. (CRNX) for the current year, now predicting US$69 million, an 11% increase from previous estimates. Despite the higher revenue projections, loss per share forecasts remained stable, suggesting increased optimism about the company's sales pipeline and growth prospects, which are expected to outpace the broader industry. This update indicates a positive shift in sentiment for Crinetics Pharmaceuticals, making it potentially an opportune time for investors to re-evaluate the company.
Industry Analysts Just Upgraded Their Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Revenue Forecasts By 11%
Industry analysts have significantly upgraded Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) revenue forecasts for 2026 by 11%, now predicting US$69 million, a 279% increase year-over-year. Despite the boosted revenue outlook, loss per share estimates remain steady at around US$4.79, and the consensus price target of US$83.21 has not changed, suggesting analysts believe ongoing losses are a larger factor in valuation than increased sales. The company is expected to grow its revenue fivefold through 2026, significantly outpacing the historical growth and the wider industry.
Crinetics Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:CRNX) 2026-05-12
Crinetics Pharmaceuticals, Inc. (CRNX) has released its Q1 2026 earnings call presentation. The company reported an EPS of -$1.23, beating expectations by $0.01, and revenue of $10.73M, exceeding estimates by $2.22M and showing a significant year-over-year increase of 2,873.41%. The article highlights that the detailed slide deck was published in conjunction with their earnings call.
Earnings call transcript: Crinetics Pharma Q1 2026 revenue beats forecast
Crinetics Pharmaceuticals Inc. (CRNX) reported Q1 2026 revenue of $10.7 million, significantly beating the forecast of $8.51 million, primarily driven by strong sales of its acromegaly treatment, PALSONIFY. Despite the revenue beat and better-than-expected EPS of -$1.23, the stock declined by 10.14% in after-hours trading. The company maintains a strong cash position of $1.3 billion, funding operations into 2030, and continues to expand PALSONIFY's market presence while advancing its clinical pipeline.
Oppenheimer Adjusts Crinetics Pharmaceuticals PT to $84 From $87, Maintains Outperform Rating
Oppenheimer has revised its price target for Crinetics Pharmaceuticals (CRNX) down to $84 from $87, while maintaining an Outperform rating on the stock. This adjustment comes despite the company reporting its Q1 2026 earnings with a slight loss but higher-than-expected revenue. The article also notes recent activities including EU approval for an acromegaly treatment and insider stock transactions.
Oppenheimer Adjusts Crinetics Pharmaceuticals PT to $84 From $87, Maintains Outperform Rating
Oppenheimer has revised its price target for Crinetics Pharmaceuticals (CRNX) to $84, down from the previous $87, while reiterating an Outperform rating. This adjustment reflects a modest change in their valuation of the pharmaceutical company.
Crinetics Pharmaceuticals (CRNX) Cash Burn And EPS Loss Reinforce Bearish Profitability Concerns
Crinetics Pharmaceuticals (CRNX) ended FY 2025 with Q4 revenue of US$6.2 million and a significant EPS loss of US$1.29, alongside a net loss of US$122.8 million. The company's large net losses compared to its limited revenue base and its forecast unprofitability over the next three years reinforce bearish concerns about its financial sustainability. While bullish investors see potential based on a discounted cash flow valuation, critics emphasize the high execution risk and ongoing cash burn.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2026 Earnings Call Transcript
Crinetics Pharmaceuticals reported strong Q1 2026 results, driven by the successful launch of Palsonify for acromegaly, which generated $10.3 million in net product revenue and enrolled 232 new patients. The company is advancing a deep clinical pipeline with four major trials and significantly expanded its prescriber base and payer coverage for Palsonify. Crinetics ended the quarter with $1.3 billion in cash, projecting funding into 2030, and is focusing on both commercial success and pipeline development for long-term value creation.
Crinetics Pharmaceuticals (CRNX) Cash Burn And EPS Loss Reinforce Bearish Profitability Concerns
Crinetics Pharmaceuticals (CRNX) reported Q4 2025 revenue of US$6.2 million and a basic EPS loss of US$1.29, with a net loss of US$122.8 million for the quarter. Trailing 12-month figures show revenue of US$7.7 million against a net loss of US$465.3 million, highlighting heavy cash burn and a limited revenue base. Analysts are concerned about persistent losses, no near-term profitability, and the need for significant scaling of multiple potential revenue streams to offset high operating costs.
Crinetics Pharmaceuticals Down Over 14%, on Pace for Largest Percent Decrease Since January 2025 -- Data Talk
Crinetics Pharmaceuticals (CRNX) stock is down over 14% and is on track for its largest single-day percentage decrease since January 2025. This significant decline follows a 4.6% increase on the previous trading day. The stock has a higher-than-average trading volume, with 2.8 million shares traded compared to its daily average of 1.2 million.
Crinetics Pharmaceuticals, Inc. (CRNX) reports Q1 loss, beats revenue estimates
Crinetics Pharmaceuticals, Inc. (CRNX) reported a loss for the first quarter that exceeded analyst expectations, though the company's revenue successfully beat estimates. This financial update provides insight into the company's performance during the recent quarter.
Earnings call transcript: CRINETICS PHARMACEUTICALS Q1 2026 beats revenue forecasts
Crinetics Pharmaceuticals (CRNX) reported strong Q1 2026 results, surpassing revenue forecasts by 25.73% with $10.7 million, largely due to the successful launch of its acromegaly treatment, PALSONIFY. EPS also exceeded expectations at -$1.23. The company's stock rose 4.27% after hours, reflecting investor confidence in its financial performance and pipeline, which includes the advanced clinical programs for atumelnant.
Crinetics Pharmaceuticals Q1 2026 Earnings Call Transcript
Crinetics Pharmaceuticals reported strong Q1 2026 results, driven by the successful launch of PALSONIFY for acromegaly, generating $10.3 million in net product revenue and expanding its prescriber base to 263. The company highlighted positive patient enrollment, growing reimbursement coverage, and the advancement of a deep clinical pipeline, including late-stage programs for atumelnant and paltusotine. Despite heavy investment in R&D, Crinetics maintains a robust balance sheet with a cash runway extending into 2030, underscoring its commitment to becoming a premier endocrine company.
Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Crinetics Pharmaceuticals reported strong first-quarter 2026 financial results, with PALSONIFY net product revenue reaching $10.3 million and robust adoption by healthcare providers for acromegaly treatment. The company also announced key regulatory approvals for PALSONIFY in Europe, an NDA submission in Japan, and progress in its clinical pipeline for atumelnant. Crinetics reaffirmed its 2026 operating expense guidance, indicating continued investment in advancing its clinical and preclinical programs.
Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Crinetics Pharmaceuticals reported strong first-quarter 2026 financial results, with PALSONIFY™ (paltusotine) generating $10.3 million in net product revenue, driven by rapid adoption and increasing prescriber confidence. The company also highlighted significant regulatory and clinical advancements for PALSONIFY in Europe, Japan, and Brazil, and provided an update on its pipeline, including the initiation of the BALANCE-CAH Phase 2/3 trial. Crinetics reaffirmed its 2026 operating expense guidance.
Earnings Flash (CRNX) Crinetics Pharmaceuticals, Inc. Reports Q1 Revenue $10.7M, vs. FactSet Est of $8.5M
Crinetics Pharmaceuticals, Inc. (CRNX) reported Q1 revenue of $10.7 million, surpassing the FactSet estimate of $8.5 million. This financial update indicates a stronger-than-expected performance for the biotechnology company during the first quarter. The article also mentions other recent news for Crinetics, including an EU approval for one of its acromegaly treatments.
232 enrollment forms as Crinetics posts $10.3M Palsonify sales
Crinetics Pharmaceuticals reported strong Q1 2026 financial results, with total revenue reaching $10.7 million, primarily driven by $10.3 million in net product revenue from PALSONIFY. The company also announced 232 PALSONIFY enrollment forms and 263 unique prescribers, alongside its European Commission approval for PALSONIFY and international regulatory filings. Despite a net loss of $127.8 million due to increased R&D and SG&A expenses, Crinetics maintained a robust cash position of $1.3 billion and reiterated its 2026 operating expense guidance.
Crinetics (NASDAQ: CRNX) posts Q1 2026 loss but builds $1.29B cash
Crinetics Pharmaceuticals reported its Q1 2026 results, showing a net loss of $127.8 million despite beginning its transition to a commercial-stage company with $10.3 million in revenue from PALSONIFY sales. The company strengthened its balance sheet with a January 2026 offering, increasing its cash, cash equivalents, and investment securities to $1.3 billion, which management believes will fund operations for at least 12 months. Significant investments continue in research and development and commercial infrastructure, leading to increased operating expenses.
Crinetics earnings on deck after European acromegaly drug win
Crinetics Pharmaceuticals Inc. is preparing to report its first-quarter results, with analysts expecting a loss of $1.28 per share on $8.51 million in revenue. This report comes after the company secured European Commission approval for its acromegaly drug, PALSONIFY, and will focus on its commercial rollout and market positioning. Despite recent stock pressure, Wall Street maintains a bullish outlook, anticipating significant upside.
Crinetics (CRNX) Q1 2026: PALSONIFY drives $10.7M revenue amid $127.8M loss
Crinetics Pharmaceuticals reported Q1 2026 revenue of $10.7 million, with PALSONIFY contributing $10.3 million from its U.S. launch for acromegaly, showing strong prescriber uptake. Despite a widened net loss of $127.8 million due to increased R&D and SG&A expenses, the company maintained a strong cash position of $1.3 billion, bolstered by a January 2026 equity offering. Crinetics reiterated its 2026 operating expense guidance and provided updates on PALSONIFY's global expansion and its late-stage pipeline.
A Look At Crinetics Pharmaceuticals (CRNX) Valuation After PALSONIFY’s EU Approval And Global Expansion Progress
Crinetics Pharmaceuticals (CRNX) has received EU approval for PALSONIFY, its oral treatment for acromegaly, expanding its market. Despite recent stock price declines, long-term holders have seen significant gains, and the company is largely considered undervalued with a fair value estimate of $82.43. However, investors also need to consider the company's P/B ratio and potential risks to PALSONIFY's sustained prescription success.
[144] Crinetics Pharmaceuticals, Inc. SEC Filing
This SEC Form 144 filing for Crinetics Pharmaceuticals (CRNX) details insider sales totaling 120,408 shares through four 10b5-1 transactions by Jeff Knight between March and April 2026, with the largest sale valued at over $3.4 million. It also reports the exercise of 8,985 stock options on May 4, 2026, and 500 Restricted Stock Units from March 15, 2025. The filing provides transparent information on the disposition of securities by an insider.
A Look At Crinetics Pharmaceuticals (CRNX) Valuation After PALSONIFY’s EU Approval And Global Expansion Progress
Crinetics Pharmaceuticals (CRNX) recently received EU approval for PALSONIFY, its oral acromegaly treatment, enhancing its global reach. Despite recent share price declines, the company is considered 52.7% undervalued with a fair value of $82.43, suggesting significant growth potential from PALSONIFY's market expansion and growing preference for oral therapies. Investors are urged to examine specific assumptions and risks impacting this valuation.
Analysts estimate Crinetics Pharmaceuticals, Inc. (CRNX) to report a decline in earnings: What to look out for
Analysts are expecting Crinetics Pharmaceuticals, Inc. (CRNX) to report a year-over-year decline in earnings for its upcoming quarterly report. The consensus EPS estimate is -$1.28, which is lower than the -$1.01 reported in the prior-year quarter. Revenue is projected to grow significantly to $2.31 million, a substantial increase from the $0.07 million seen in the same quarter last year.
Crinetics Pharmaceuticals (CRNX): Billionaire Tom Steyer Likes This Pharma Stock
Billionaire Tom Steyer's firm, Farallon Capital, has significantly increased its stake in Crinetics Pharmaceuticals (CRNX), holding nearly 7 million shares as of Q4 2025. The primary driver for CRNX is the global launch of PALSONIFY, the first once-daily oral treatment for acromegaly, which has received approval in both the US and Europe. Analysts are projecting robust revenue growth for PALSONIFY, with early adoption exceeding expectations.
Does EU Approval Of Oral Acromegaly Drug PALSONIFY Redefine The Bull Case For Crinetics (CRNX)?
Crinetics Pharmaceuticals received EU approval for its oral acromegaly drug, PALSONIFY, which expands its market and supports its shift towards oral therapies. While the approval boosts the long-term outlook, the company's immediate success hinges on launch execution and prescription growth. Crinetics has a strong cash balance of $1.1 billion, expected to fund operations into 2029, providing a buffer for potential early uptake challenges despite ongoing losses.
Crinetics Pharmaceuticals Inc (HAM:6Z4) Stock Price, Trades & News
Crinetics Pharmaceuticals Inc (HAM:6Z4) is a commercial-stage pharmaceutical company focused on rare endocrine diseases, with its main product Palsonify approved by the FDA for acromegaly. The company shows a market capitalization of €3.49 billion and is currently unprofitable. GuruFocus has detected three severe warning signs for the stock, and its next earnings release is scheduled for May 7, 2026.
Q2 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript
This transcript covers Crinetics Pharmaceuticals Inc.'s Q2 2025 earnings call, highlighting the company's strong financial position with $1.2 billion in cash and investments, funding operations into 2029. Key positive points include the anticipated FDA approval of Paltusine in September, progress in pipeline programs for carcinoid syndrome and congenital adrenal hyperplasia, and extensive engagement with healthcare professionals. Negative aspects discussed are the significant increases in R&D and SG&A expenses, uncertainty regarding IND submission timelines, and potential challenges for Paltusine's market uptake due to infrequent patient visits.
Crinetics Pharmaceuticals Inc (HAM:6Z4) - Valuation Measures & Financial Statistics
This article provides a detailed breakdown of the valuation measures and financial statistics for Crinetics Pharmaceuticals Inc (HAM:6Z4) as presented on GuruFocus. It lists various financial metrics categorized under fundamental, valuation ratio, profitability, price, dividends, income statement, balance sheet, and cash flow statement, offering a comprehensive overview of the company's financial health and performance indicators.
Vanguard Capital Management holds 5.19% of Crinetics (NASDAQ: CRNX)
Vanguard Capital Management has reported a beneficial ownership of 5,440,646 shares, representing 5.19% of Crinetics Pharmaceuticals Inc (CRNX) common stock. The Schedule 13G filing indicates Vanguard has sole dispositive power over all these shares and sole voting power over 766,711 shares. The document was signed on April 29, 2026, by Ashley Grim.
Pictet Asset Management Holding SA Has $72.63 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. $CRNX
Pictet Asset Management Holding SA has increased its stake in Crinetics Pharmaceuticals, Inc. (CRNX) by 6.5%, now owning 1,560,300 shares valued at $72.63 million. This comes as company insiders have been net sellers, while institutional investors hold the majority of the stock. Analysts have a "Moderate Buy" consensus rating with a target price of $76.75, despite recent stock declines.
Crinetics (NASDAQ: CRNX) details 2026 meeting, board votes and auditor change
Crinetics Pharmaceuticals will hold its 2026 annual shareholder meeting virtually on June 18, 2026. Shareholders will vote on electing three Class II directors, ratifying PricewaterhouseCoopers LLP as the independent auditor for 2026, and an advisory "say-on-pay" vote for executive compensation. The company also announced the dismissal of BDO USA, P.C. as their independent auditor, effective February 27, 2026, and the appointment of PwC.
Crinetics Pharmaceuticals Files Marketing Application for Acromegaly Drug in Brazil
Crinetics Pharmaceuticals has filed a Marketing Authorization Application in Brazil for Palsonify, an oral treatment for acromegaly, expanding its global presence. Supported by positive clinical trial data, including two Phase 3 studies, the drug has also received a positive opinion from the European CHMP. The company's CEO emphasized the significance of this move for its international strategy and the medication's impact on care standards.
5 Best Biotech Stocks with Highest Upside Potential
This article highlights Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) as one of the top biotech stocks with high upside potential, noting its strongly bullish consensus and over 126% potential upside according to analysts. The company recently filed a Marketing Authorization Application in Brazil for its acromegaly treatment, Palsonify, following its successful FDA approval in the US. Crinetics is also developing other therapies for endocrine diseases that are currently in various stages of clinical trials.
CRNX Maintains Market Outperform Rating -- Price Target Raised t
Crinetics Pharmaceuticals (CRNX) has had its price target increased to $97.00 by Citizens analyst Jonathan Wolleben, who maintains a "Market Outperform" rating. Despite a significant undervaluation according to GuruFocus's GF Value™, the company faces challenges in profitability and growth, reflected in its low GF Score™ of 45. Additionally, recent insider selling of $5.6 million worth of shares signals potential caution regarding the company's short-term prospects.
Crinetics receives EU approval for acromegaly drug Palsonify By Investing.com
Crinetics Pharmaceuticals has received EU approval for its acromegaly drug, Palsonify, for adult patients. This marks the company's first regulatory clearance outside the U.S., with plans to commence commercialization in Germany and Austria. The approval was based on positive results from two Phase 3 trials, PATHFNDR-1 and PATHFNDR-2, showing efficacy in biochemical control and symptom reduction.
EU approves first once-daily pill for acromegaly from Crinetics
Crinetics Pharmaceuticals announced that the European Commission has approved PALSONIFY (paltusotine), making it the first once-daily oral therapy for acromegaly in the EU. This approval, based on positive Phase 3 trial data, covers all 27 EU member states and three EEA countries, marking Crinetics' first regulatory success outside the U.S. Initial launches are planned for Germany and Austria, while the company also pursues approvals in Japan and Brazil.
A Look At Crinetics Pharmaceuticals (CRNX) Valuation After Mixed Recent Share Performance
Crinetics Pharmaceuticals has experienced mixed recent share performance, with short-term declines alongside longer-term gains. Despite recent weakness, the company is considered undervalued by a key narrative that pegs its fair value at $82.43 per share, significantly higher than its current trading price of $38.33, driven by expectations of future revenue growth from its clinical pipeline, particularly PALSONIFY. However, this optimistic outlook could be challenged by slower-than-expected uptake of PALSONIFY or further pipeline delays.
A Look At Crinetics Pharmaceuticals (CRNX) Valuation After Mixed Recent Share Performance
Crinetics Pharmaceuticals (CRNX) has shown mixed recent share performance, with short-term declines contrasting with positive long-term returns. Simply Wall St's analysis suggests the company's fair value is $82.43 per share, significantly higher than its current trading price of $38.33, based on potential revenue growth from its clinical pipeline, particularly PALSONIFY. However, this optimistic outlook is subject to risks such as slower-than-expected uptake or further pipeline delays.
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
Crinetics Pharmaceuticals, Inc. announced that the European Commission (EC) has approved PALSONIFY® (paltusotine) for the treatment of adult patients with acromegaly. This approval marks the first once-daily, oral therapy for acromegaly in the EU and is based on positive results from two pivotal Phase 3 trials, PATHFNDR-1 and PATHFNDR-2. Crinetics plans to launch PALSONIFY initially in Germany and Austria, expanding its global presence for this new standard in acromegaly care.
A Look At Crinetics Pharmaceuticals (CRNX) Valuation After Mixed Recent Share Performance
Crinetics Pharmaceuticals (CRNX) has experienced mixed share performance recently, with short-term declines but positive long-term returns. Simply Wall St values Crinetics at $82.43 per share, significantly above its current trading price, based on the potential of its clinical pipeline, particularly PALSONIFY for acromegaly, and anticipated revenue growth. However, this optimistic outlook depends on strong PALSONIFY uptake and avoiding further pipeline delays.
Trading the Move, Not the Narrative: (CRNX) Edition
This article provides an analysis of Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) focusing on "trading the move, not the narrative." It highlights weak near-term sentiment but strong mid- and long-term signals, offering three distinct AI-generated trading strategies. The piece includes technical signals, support and resistance levels across multiple timeframes, and emphasizes risk management for optimizing positions.
